Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 140

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 140
---
 Diagnostics services to diagnostic laboratories, which provide our tests to hospitals, medical institutions and other laboratories. Since Rewell was launched, we also provide genetic and microbiome tests as direct -to -customerto the general population. Healthcare policy changes that influence the way healthcare is financed or other changes in the market that impact payment rates by institutional or non -institutionalcustomers could also affect our collection rates. If we are unable to convince our distributors and overall consumers of the value and benefit provided by our services, these customers may slow, or stop altogether, their purchases of our tests. We currently do not offer reimbursement to patients in connection with our tests. As such, if in the future third -partypayors do not provide coverage and adequate reimbursement for our tests and testing services, our potential for growth and our ability to collect revenue for these tests and testing services would be limited. 46 Even if payers eventually agree to cover our tests, our billing and collections process may be complicated by the following and other factors, which may be beyond our control: •disputes among payers as to which payer is responsible for payment; •disparity in coverage among various payers or among various healthcare plans offered by a single payer; •payer medical management requirements, including prior authorization requirements; •differing information and billing requirements among payers; •failure by patients or healthcare providers to provide complete and correct billing information; and •limitations and requirement for patient billing, including those related to deductibles, co -payments, and co -insuranceoriginating from contracts with commercial payers. Moreover, our ability to collect payment for our tests and testing services in a timely manner or at all from our customers may decline to the extent we expand our business into new customer groups, including individual physicians, nutritionists and other practitioners, from which collection rates are often significantly lower than distributors in the health industry and which involve substantial additional risks that are discussed in these risk factors below. Our collection risks also include the potential for default or bankruptcy by the party responsible for payment and other risks associated with payment collection generally. Any inability to maintain our past payment collection levels could cause our revenue and ability to achieve profitability to decline and adversely affect our business, prospects and financial condition. The uncertainty of receiving payment for our tests and complex laboratory billing processes could negatively affect our business, financial condition, results of operations and growth prospects. We may incur significant losses from fraud. We may in the future incur losses from various types of fraud, including stolen credit card numbers, claims that a customer